AGN News and Press, Allergan plc From 08/18/19

AbbVie ( ABBV ) announced that it had received FDA approval for updatacitinib to be marketed as RINVOQ. It was approved to treat patients with rheumatoid arthritis. It is estimated that this drug alone for this indication could bring in multi-billion dollars for the company. This is good n...

Four of my favorite times of the trading year are the days that Form 13F filings are released. Those filings give all investors and traders a chance to see what the big money is buying, selling or holding. In particular I am interested in the funds that invest largely in M&A stocks. I tr...

This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 08/13/2019. Please visit our Tracking Seth Klarman's Baupost Group Holdings article for a...

Merger activity increased last week with seven new deals announced and four pending deals closing. In the context of the merger of Sprint (S) with T-Mobile (TMUS), it was interesting to see a large insider purchase by the Chairman of DISH Network (DISH). Deal Statistics: New Deals: ...

JPMorgan Chase ( JPM +2.2% ) is set to collect the largest individual fee to a bank for selling a company -- $123M for advising Allergan ( AGN +0.9% ) on its planned $63B sale to AbbVie, the Financial Times reports, citing data from Dealogic. More news on: JPMorgan Chase & Co.,...

By Breakingviews Bloodletting is largely discredited as a way of curing the sick. Yet some regional newspaper operators are still giving it a shot. New Media Investment (NEWM) wants to pay $1.4 billion in cash and shares for Gannett (GCI), making the biggest publisher of local papers in th...

The following segment was excerpted from this fund letter . Last fall I converted our equity investment in Allergan (AGN) into long-term call options expiring in 2021 with strike prices between $125 and $150 for reasons I covered in the prior letter. At the end of last December when the s...

These are tough times for yield seekers. The yields in many defensive, typically higher dividend-paying sectors, as well as long duration Treasury bonds, have been driven down by fears of an economic slowdown and the specter of a looming recession. Investors have piled heavily into consumer ...

Neurocrine Biosciences (NASDAQ: NBIX ) initiated with Outperform rating and $118 (24% upside) price target at RBC. More news on: Neurocrine Biosciences, Inc., Regeneron Pharmaceuticals, Inc., Allergan plc, Healthcare stocks news, Stocks on the move, , Read more ...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify (click the highlighted links). Markets are getting some more relief as the PBOC set its official midpoint reference for the yuan at...